Authors: Boucher, Yves; Kumar, Ashwin S.; Posada, Jessica M.; Gjini, Evisa; Pfaff, Kathleen; Lipschitz, Mikel; Lako, Ana; Duda, Dan G.; Rodig, Scott J.; Hodi, F. Stephen; Jain, Rakesh K.
Issue: NPJ Precis Oncol. 2021 Jun 29;5(1):62.
A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.